Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial
Despite the substantial clinical activity of fms-related tyrosine kinase 3 (FLT3) inhibitors in relapsed or refractory (R/R) FLT3-ITD‒positive acute myelogenous leukemia (AML), durable remissions and prolonged survival in this population require allogeneic hematopoietic stem cell transplantation (al...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Transplantation and cellular therapy
Year: 2020, Jahrgang: 27, Heft: 2, Pages: 153-162 |
| ISSN: | 2666-6367 |
| DOI: | 10.1016/j.bbmt.2020.09.036 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.bbmt.2020.09.036 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1083879120306297 
|
| Verfasserangaben: | Siddhartha Ganguly, Jorge E. Cortes, Alwin Krämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Cedric Dos Santos, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Hoang Pham, Yibin Wang, Samer K. Khaled |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1755146795 | ||
| 003 | DE-627 | ||
| 005 | 20240413193258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210416r20212020xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbmt.2020.09.036 |2 doi | |
| 035 | |a (DE-627)1755146795 | ||
| 035 | |a (DE-599)KXP1755146795 | ||
| 035 | |a (OCoLC)1341404858 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Ganguly, Siddhartha |e VerfasserIn |0 (DE-588)1231820942 |0 (DE-627)1755431333 |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial |c Siddhartha Ganguly, Jorge E. Cortes, Alwin Krämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Cedric Dos Santos, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Hoang Pham, Yibin Wang, Samer K. Khaled |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 21 December 2020 | ||
| 500 | |a Gesehen am 20.04.2021 | ||
| 520 | |a Despite the substantial clinical activity of fms-related tyrosine kinase 3 (FLT3) inhibitors in relapsed or refractory (R/R) FLT3-ITD‒positive acute myelogenous leukemia (AML), durable remissions and prolonged survival in this population require allogeneic hematopoietic stem cell transplantation (allo-HSCT). Quizartinib, a once-daily oral, highly potent, and selective FLT3 inhibitor, significantly prolonged overall survival (OS) and improved clinical benefit compared with salvage chemotherapy (median OS, 6.2 months versus 4.7 months; hazard ratio [HR], .76; 95% confidence interval [CI], .58 to .98; P = .018; composite complete remission [CRc] rate, 48% versus 27%; median duration of CRc, 2.8 months versus 1.2 months; mortality rate, .8% versus 14% by day 30, 7% versus 24% by day 60) in patients with R/R FLT3-ITD AML in the phase 3 QuANTUM-R trial. In this post hoc analysis, we described the characteristics of and clinical outcomes in patients who underwent on-study HSCT in QuANTUM-R at the investigator's discretion and institutional practices. Of 367 randomized patients, 78 (32%) in the quizartinib arm and 14 (11%) in the salvage chemotherapy arm underwent on-study allo-HSCT without any intervening therapy for AML after quizartinib or study-specified salvage chemotherapy. Pooled data of patients from both treatment arms showed a longer median overall survival (OS) in transplant recipients versus those treated without allo-HSCT (12.2 months versus 4.4 months; HR, .315; 95% CI, .233 to .427). Pooled data also showed a longer median OS in patients with a last recorded response of CRc before allo-HSCT versus patients without a CRc (20.1 months versus 8.8 months; HR, .506; 95% CI, .296 to .864). By treatment arm, the median OS was 25.1 months with quizartinib and 20.1 months with salvage chemotherapy in patients with a last recorded response of CRc before allo-HSCT. Forty-eight patients in the quizartinib arm continued quizartinib treatment after allo-HSCT. In the 31 patients with a last recorded response of CRc before allo-HSCT who continued quizartinib after allo-HSCT, the median OS was 27.1 months. Continuation of quizartinib after allo-HSCT was tolerable, and no new safety signals were identified. These results suggest that post-transplantation survival following salvage chemotherapy and quizartinib treatment are similar. However, quizartinib response occurs more frequently than with salvage chemotherapy, potentially allowing more patients to undergo transplantation and achieve durable clinical benefit. In addition, post-transplant quizartinib was found to be tolerable and may be associated with prolonged survival in some patients, highlighting its potential value in the management of patients with FLT3-ITD R/R AML. | ||
| 534 | |c 2020 | ||
| 650 | 4 | |a Acute myelogenous leukemia | |
| 650 | 4 | |a Allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a FMS-related tyrosine kinase 3 internal tandem duplication | |
| 650 | 4 | |a Quizartinib | |
| 650 | 4 | |a Relapsed/refractory | |
| 700 | 1 | |a Cortes, Jorge E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krämer, Alwin |e VerfasserIn |0 (DE-588)1067780025 |0 (DE-627)819183431 |0 (DE-576)426900820 |4 aut | |
| 700 | 1 | |a Levis, Mark J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martinelli, Giovanni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Perl, Alexander E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Russell, Nigel H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Arunachalam, Meena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Santos, Cedric Dos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gammon, Guy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lesegretain, Arnaud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mires, Derek E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pham, Hoang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Yibin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khaled, Samer K. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation and cellular therapy |d [Amsterdam] : Elsevier B. V., 2021 |g 27(2021), 2, Seite 153-162 |h Online-Ressource |w (DE-627)1750919230 |w (DE-600)3056525-X |x 2666-6367 |7 nnas |a Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:2 |g pages:153-162 |g extent:10 |a Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bbmt.2020.09.036 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1083879120306297 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210416 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1067780025 |a Krämer, Alwin |m 1067780025:Krämer, Alwin |d 910000 |d 910100 |d 50000 |e 910000PK1067780025 |e 910100PK1067780025 |e 50000PK1067780025 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1755146795 |e 3910862241 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial","title":"Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1755146795","origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"physDesc":[{"extent":"10 S."}],"id":{"eki":["1755146795"],"doi":["10.1016/j.bbmt.2020.09.036"]},"relHost":[{"pubHistory":["Volume 27, issue 1 (January 2021)-"],"title":[{"title":"Transplantation and cellular therapy","title_sort":"Transplantation and cellular therapy"}],"language":["eng"],"part":{"issue":"2","pages":"153-162","extent":"10","text":"27(2021), 2, Seite 153-162","year":"2021","volume":"27"},"titleAlt":[{"title":"TCT"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"1750919230","origin":[{"publisher":"Elsevier B. V.","dateIssuedDisp":"2021-","dateIssuedKey":"2021","publisherPlace":"[Amsterdam]"}],"disp":"Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trialTransplantation and cellular therapy","id":{"eki":["1750919230"],"issn":["2666-6367"],"zdb":["3056525-X"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 10.03.21"]}],"note":["Available online 21 December 2020","Gesehen am 20.04.2021"],"name":{"displayForm":["Siddhartha Ganguly, Jorge E. Cortes, Alwin Krämer, Mark J. Levis, Giovanni Martinelli, Alexander E. Perl, Nigel H. Russell, Meena Arunachalam, Cedric Dos Santos, Guy Gammon, Arnaud Lesegretain, Derek E. Mires, Hoang Pham, Yibin Wang, Samer K. Khaled"]},"person":[{"family":"Ganguly","display":"Ganguly, Siddhartha","role":"aut","given":"Siddhartha"},{"family":"Cortes","display":"Cortes, Jorge E.","role":"aut","given":"Jorge E."},{"family":"Krämer","given":"Alwin","role":"aut","display":"Krämer, Alwin"},{"family":"Levis","display":"Levis, Mark J.","role":"aut","given":"Mark J."},{"role":"aut","given":"Giovanni","display":"Martinelli, Giovanni","family":"Martinelli"},{"family":"Perl","given":"Alexander E.","role":"aut","display":"Perl, Alexander E."},{"role":"aut","given":"Nigel H.","display":"Russell, Nigel H.","family":"Russell"},{"family":"Arunachalam","given":"Meena","role":"aut","display":"Arunachalam, Meena"},{"family":"Santos","display":"Santos, Cedric Dos","given":"Cedric Dos","role":"aut"},{"display":"Gammon, Guy","role":"aut","given":"Guy","family":"Gammon"},{"family":"Lesegretain","display":"Lesegretain, Arnaud","role":"aut","given":"Arnaud"},{"family":"Mires","role":"aut","given":"Derek E.","display":"Mires, Derek E."},{"family":"Pham","display":"Pham, Hoang","role":"aut","given":"Hoang"},{"given":"Yibin","role":"aut","display":"Wang, Yibin","family":"Wang"},{"family":"Khaled","role":"aut","given":"Samer K.","display":"Khaled, Samer K."}]} | ||
| SRT | |a GANGULYSIDCLINICALOU2021 | ||